B+
Bull case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
VOR
Vor BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.6
Score
AI commentary
Post-print sentiment is neutral-to-cautious. The primary filing confirms continued Phase 3 development and meaningful liquidity, but also substantial warrant liabilities and ongoing losses. Analyst reaction, consensus surprise data, transcript commentary, and a reliable earnings-specific price attribution were unavailable, so confidence remains limited despite the strong primary-source record.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-11eventQ2 2026 filing confirms liquidity but highlights warrant and loss volatilityHigh impact
The June 30, 2026 10-Q reported $466.1 million of cash and marketable securities, but also $653.9 million of warrant liabilities, a $200.2 million stockholders' deficit, and continued operating losses. No reliable consensus surprise or analyst reaction was available. [#SEC-10Q-2026-08-11]
2026-11-11catalystFinancing, dilution, and clinical execution overhangHigh impact
Vor remains a clinical-stage company without commercial revenue, expects continued losses, and states that substantial additional funding may be required. Large warrant liabilities and prior open-market sales by RA Capital add financing and supply risks. [#SEC-10Q-2026-08-11][#SEC-FORM4-2026-04-24]
2027-08-13catalystUPSTREAM MG Phase 3 topline dataHigh impact
Vor Bio is continuing enrollment in the global Phase 3 UPSTREAM MG trial of telitacicept, with topline results anticipated in the first half of 2027. [#PR-EARNINGS-2026-05-13][#SEC-10Q-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology